Abstract
Background: Brodalumab is a fully human anti–interleukin-17 (IL-17) receptor A monoclonal antibody efficacious for the treatment of moderate to severe plaque psoriasis in adults. Limited information on the characteristics of those receiving brodalumab in a real-world setting exists. We describe baseline characteristics of Corrona Psoriasis Registry patients who initiated brodalumab, relative to other biologics for psoriasis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
